Oncolytics Biotech Inc. · NASDAQ:ONCY
Oncolytics Biotech — Investor Presentation (October 2025)
21 slides from Oncolytics Biotech's investor presentation, Oct 10, 2025
Slide 1: Pelareorep: a transformative dsRNA immunotherapy platform for gastrointestinal tumors
PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors October 2025 Oncolytics Biotech Exhibit 99.1
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Overview Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any representation to the contrary is a criminal offense. This presentation does
Slide 3: Mission
MISSION We will leverage our proprietary product candidate, pelareorep (pela), an investigational first-in-class double-stranded RNA immunotherapeutic agent, to establish a platform immunotherapy for the treatment of gastrointestinal (GI) tumors. We believe GI tumors are the largest unmet medical ne
Slide 4: Pela mechanism of action: intravenous delivery to tumor and immune activation
4 Intravenous administration Pela delivery to tumor Some tumor cells are killed by pela infection Hot tumor secretes type I IFN & chemokines Chemokines and cytokines activate TIL clones in LN Expanded TIL clones in blood are attracted to the tumor by chemokines Activated TIL clones destroy tumor cel
Slide 5: Pelareorep observed to replicate in almost all evaluated tumors
5 Indication treated with IV Pela # of biopsied tumors # Pela-positive biopsies Pancreatic ductal adenocarcinoma 12 12 Metastatic colorectal cancer 12 11 Head and neck cancer 3 3 Gliomas/metastatic brain tumors 9 8 Relapsed multiple myeloma 20 20 Primary breast cancer 23 23 Other 4 4 1. Berkeley, et
Slide 6: Pelareorep safety and tolerability profile
6 Most common PELA-adverse reactions: • “Flu-like” symptoms: Fever, chills, headache, fatigue, myalgia, cough, anorexia • GI symptoms also common: Nausea, diarrhea, vomiting • Lymphopenia, neutropenia, thrombocytopenia also common, but rarely clinically significant • No maximum tolerated dose (MTD)
Slide 7: Market opportunity within pelareorep's targeted indications
• ~ 500,000 patients globally1 • ~ $3 billion total addressable market with 15% CAGR to 20322 • Chemotherapy standard of care with no approved immunotherapy • 3% mPDAC 5-year survival rate3 • ~ 1,900,000 patients globally 4 • ~ $12.5 billion total addressable market with 4.7% CAGR to 2033 5 • KRAS m
Slide 8: Pelareorep Clinical Development
PELAREOREP CLINICAL DEVELOPMENT
Slide 9: Clinical proof of concept across targeted indications guides strategic sequencing
9 Targeted indication SOC benchmark* Pela Data Delta 2L mCRC (KRAS mutant) OS: 11.2 mo, PFS: 5.7 mo1 OS: 27 mo, PFS: 16.6 mo8 ~ 2-3x ≥2L SCAC ORR: 11-24%2-5 ORR: 30% ~ 1.5-3x 1L mPDAC 2-year OS rate: ~ 9%6, 7 2-year OS rate: ~ 22%6 ~ 2.5x CLINICAL POC ACROSS TARGETED INDICATIONS GUIDES STRATEGIC SEQ
Slide 10: Development programs and anticipated milestones
10 2L SCAC GOBLET cohort 4 ≥2L Unresectable SCAC pela + atezo Data expected Q4 2025; US sites open 1H 2026 Pivotal Study TBD pela + CPI Potential single-arm study launch Q3 2026 Program Collaborator Combination Phase 1 Phase 2 Registration-Enabling Phase 3 Anticipated Milestone 1L PDAC Pivotal Study
Slide 11: Pancreatic Cancer Program
PANCREATIC CANCER PROGRAM *Received FDA Fast Track & Orphan Drug Designations
Slide 12: Clinical results of pelareorep in first-line mPDAC studies
12 Clinical results of pelareorep in first-line mPDAC studies Company (Study) Description (Patients) 1-Year Survival 2-Year Survival Notes Oncolytics (REO 017) Pelareorep + Gemcitabine (34 patients) 45% vs. 22% 24% vs. 4% DCR: 83% vs. 33% Single arm vs. gemcitabine benchmark Oncolytics/NCI (NCI 8601
Slide 13: 2-year survival rate versus comparator treatment arms
13 24.0% REO 017: Pela + G NCI 8601: Pela + CP Study Carrato: GnP + mFOLFOX Carrato: GnP Okusaka: Gem + S1 Okusaka: S1 Conroy: FOLFIRINOX Okusaka: Gem Von Hoff: GnP Von Hoff: Gem Conroy: Gem Weighted mean of comparator arms 2-year Survival Rate 0% 10% 20% 30% 22.4% 9.2% 4.6% 9.0% 4.0% 7.6% 9.4% 10.9
Slide 14: Colorectal Cancer Program
COLORECTAL CANCER PROGRAM >
Slide 15: Efficacy results for pelareorep in colorectal cancer
15 Translational data from REO 022 and REO 013 studies support observed benefit1, 7, 8: • Viral replication and immune activation shown in mCRC tumors • Dendritic cell maturation and CD8+ T cell activation alter TME and enabled tumors to respond to treatment REO 022 study in 2L KRAS mutant mCRC resu
Slide 16: Anal Cancer Program
ANAL CANCER PROGRAM
Slide 17: Pela + atezo in ≥2L SCAC
17 ORR: objective response rate; 2L: second-line; SCAC: squamous cell carcinoma of the anal canal; pela: pelareorep; atezo: atezolizumab; DCR: disease control rate; CR: complete response; PR: partial response; PD: progressive disease; SD: stable disease *Complete response (CR) recorded by the invest
Slide 18: Regulatory, Intellectual Property and Manufacturing
REGULATORY, INTELLECTUAL PROPERTY AND MANUFACTURING
Slide 19: Regulatory and Commercial Strategy
19 Regulatory Strategy • Proof of concept solidly established in three GI tumors • Focus on most efficient regulatory path in high unmet medical need indications with large commercial potential • Utilize regulatory designations and biomarker driven studies • 1L PDAC study with chemo and CPI expected
Slide 20: IP profile and manufacturing characteristics
Patent numbers as of June 30, 2025 20 Intellectual Property • 147 patents issued worldwide • New patents expected to extend manufacturing and method of use protection into 2044 • Composition of matter protection through 2028 • Existing method of use and manufacturing protection through 2031 • Pendin
Slide 21: Innovative leadership team
21 Kirk Look, CA, MSJ Chief Financial Officer Thomas Heineman, M.D., Ph.D. Chief Medical Officer Allison Hagerman, PEng, PMP, MBT VP, Product Development Amy Levin, RN, BSN VP, Clinical Operations Andrew Aromando Chief Business Officer Jared Kelly Chief Executive Officer Board Member INNOVATIVE LEAD
Oncolytics Biotech — Investor Presentation (October 2025) on 6ix